Autoimmunity BioSolutions Raises $1M in Seed Extension Funding

The company plans to use the funding to expand operations and continue developing its technology and products.

Eos BioInnovation led the funding round, alongside a group of family offices that support long-term investments. The investors believe in ABS’s unique scientific platform and its potential to improve treatment outcomes for millions of patients with autoimmune diseases who are not well served by current therapies.

ABS’s research team identified a common genetic variation (SNP) found in about 50% of the population that can increase circulating sIL7R levels by 2–3 times. Higher sIL7R levels have been linked to more severe disease, faster disease progression, and weaker response to standard treatments in autoimmune diseases such as Rheumatoid Arthritis, Lupus Nephritis, and Type 1 Diabetes.

"We are grateful for the continued support of our family office partners, whose participation in this seed extension reflects shared belief in the transformative potential of our platform," said Eugene Williams MBA, Chief Executive Officer, Autoimmunity BioSolutions. "With the participation of seasoned investors who understand the pace and promise of life sciences innovation, we are well positioned to deploy this capital with purpose, completing important animal model work and patient bio sample analyses in our lead indication of Rheumatoid Arthritis, building on the compelling scientific momentum already underway at ABS."

Read More:Avant Genomics Raises $3M+ in Funding

About Autoimmunity BioSolutions (ABS)

Founded by Gaddiel Galarza-Munoz, Autoimmunity BioSolutions (ABS) is developing a personalized therapy to lower elevated levels of the soluble IL-7 receptor (sIL-7R), which is linked to poor treatment response in autoimmune diseases. The therapy focuses on patients with a common genetic variant (SNP) that increases sIL7R levels and is associated with more severe disease, faster progression, and weaker response to existing treatments.

Unlike many current treatments that suppress the immune system, ABS aims to correct the underlying immune imbalance by targeting sIL7R in patients with a genetic predisposition. The company believes this approach could improve treatment response for difficult to treat autoimmune patients across multiple diseases.

Read More:Outmarket AI Raises $17M in Series A Funding